메뉴 건너뛰기




Volumn 9, Issue , 2012, Pages

Current status and future directions in the management of chronic hepatitis C

Author keywords

Antiviral; Cirrhosis; Fibrosis; Hepatic carcinoma; Hepatitis C; Prevention; Treatment

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; ALISPORIVIR; ANTIVIRUS AGENT; BALAPIRAVIR; BI 12202; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DANOPREVIR; HEPATITIS C VACCINE; MERICITABINE; MK 0608; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VIRUS RNA; VIRUS VACCINE;

EID: 84857683435     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-5722385500     Document Type: Review
Times cited : (52)

References (81)
  • 2
    • 6044247223 scopus 로고    scopus 로고
    • The evolving treatment of chronic hepatitis C: Where we stand a decade out
    • 15468610
    • The evolving treatment of chronic hepatitis C: where we stand a decade out. Saadeh S Davis GL, Cleve Clin J Med 2004 71 Suppl 3 3 7 15468610
    • (2004) Cleve Clin J Med , vol.71 , Issue.SUPPL. 3 , pp. 193-197
    • Saadeh, S.1    Davis, G.L.2
  • 3
    • 33748757526 scopus 로고    scopus 로고
    • Human schistosomiasis
    • DOI 10.1016/S0140-6736(06)69440-3, PII S0140673606694403
    • Human schistosomiasis. Gryseels B Polman K, Clerinx J Kestens L, Lancet 2006 368 1106 1118 10.1016/S0140-6736(06)69440-3 16997665 (Pubitemid 44402679)
    • (2006) Lancet , vol.368 , Issue.9541 , pp. 1106-1118
    • Gryseels, B.1    Polman, K.2    Clerinx, J.3    Kestens, L.4
  • 4
    • 76149141825 scopus 로고    scopus 로고
    • Hepatitis C virus: Molecular biology & current therapeutic options
    • 20167971
    • Hepatitis C virus: molecular biology & current therapeutic options. Sharma SD, Indian J Med Res 2010 131 17 34 20167971
    • (2010) Indian J Med Res , vol.131 , pp. 17-34
    • Sharma, S.D.1
  • 5
    • 84859769302 scopus 로고    scopus 로고
    • Global Alert and Response (GAR), Hepatitis C
    • Global Alert and Response (GAR), Hepatitis C. World Health Organization 2002
    • (2002) World Health Organization
  • 6
    • 74749100404 scopus 로고    scopus 로고
    • Interferon therapy of hepatitis C: Molecular insights into success and failure
    • 19950038
    • Interferon therapy of hepatitis C: molecular insights into success and failure. Sarasin-Filipowicz M, Swiss Med Wkly 2010 140 3 11 19950038
    • (2010) Swiss Med Wkly , vol.140 , pp. 3-11
    • Sarasin-Filipowicz, M.1
  • 8
    • 33749259433 scopus 로고    scopus 로고
    • Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment
    • Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. Caruntu FA Benea L, J Gastrointestin Liver Dis 2006 15 249 256 17013450 (Pubitemid 44483093)
    • (2006) Journal of Gastrointestinal and Liver Diseases , vol.15 , Issue.3 , pp. 249-256
    • Caruntu, F.A.1    Benea, L.2
  • 11
    • 77955359911 scopus 로고    scopus 로고
    • Treatment of hepatitis C in children: A systematic review
    • 10.1371/journal.pone.0011542. 20644626
    • Treatment of hepatitis C in children: a systematic review. Hu J Doucette K Hartling L Tjosvold L, Robinson J,, PLoS One 2010 5 11542 10.1371/journal. pone.0011542 20644626
    • (2010) PLoS One , vol.5 , pp. 511542
    • Hu, J.1    Doucette, K.2    Hartling, L.3    Tjosvold, L.4    Robinson, J.5
  • 12
    • 77954774460 scopus 로고    scopus 로고
    • Managing HCV infection in pediatric age group: Suggested recommendations
    • 10.4103/1319-3767.65182. 20616426
    • Managing HCV infection in pediatric age group: suggested recommendations. Danish FA Koul SS Subhani FR Rabbani AE, Yasmin S,, Saudi J Gastroenterol 2010 16 230 235 10.4103/1319-3767.65182 20616426
    • (2010) Saudi J Gastroenterol , vol.16 , pp. 230-235
    • Danish, F.A.1    Koul, S.S.2    Subhani, F.R.3    Rabbani, A.E.4    Yasmin, S.5
  • 13
    • 1242340436 scopus 로고    scopus 로고
    • Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life
    • DOI 10.1136/gut.2003.027581
    • Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Hickman IJ Jonsson JR Prins JB Ash S, Purdie DM Clouston AD, Powell EE,, Gut 2004 53 413 419 10.1136/gut.2003.027581 14960526 (Pubitemid 38241340)
    • (2004) Gut , vol.53 , Issue.3 , pp. 413-419
    • Hickman, I.J.1    Jonsson, J.R.2    Prins, J.B.3    Ash, S.4    Purdie, D.M.5    Clouston, A.D.6    Powell, E.E.7
  • 14
    • 0032924020 scopus 로고    scopus 로고
    • Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
    • Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hourigan LF Macdonald GA Purdie D Whitehall VH, Shorthouse C Clouston A, Powell EE,, Hepatology 1999 29 1215 1219 10.1002/hep.510290401 10094967 (Pubitemid 29168757)
    • (1999) Hepatology , vol.29 , Issue.4 , pp. 1215-1219
    • Hourigan, L.F.1    Macdonald, G.A.2    Purdie, D.3    Whitehall, V.H.4    Shorthouse, C.5    Clouston, A.6    Powell, E.E.7
  • 15
    • 77954281477 scopus 로고    scopus 로고
    • Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis
    • 20386865
    • Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mas VR Fassnacht R, Archer KJ Maluf D, Mol Med 2010 16 287 297 20386865
    • (2010) Mol Med , vol.16 , pp. 287-297
    • Mas, V.R.1    Fassnacht, R.2    Archer, K.J.3    Maluf, D.4
  • 16
    • 77950827009 scopus 로고    scopus 로고
    • Impact of alcohol on hepatitis C virus replication and interferon signaling
    • 10.3748/wjg.v16.i11.1337. 20238400
    • Impact of alcohol on hepatitis C virus replication and interferon signaling. McCartney EM Beard MR, World J Gastroenterol 2010 16 1337 1343 10.3748/wjg.v16.i11.1337 20238400
    • (2010) World J Gastroenterol , vol.16 , pp. 1337-1343
    • McCartney, E.M.1    Beard, M.R.2
  • 25
    • 33745713376 scopus 로고    scopus 로고
    • A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
    • 10.1016/j.jhep.2006.03.008. 16780997
    • A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Silva M Poo J, Wagner F Jackson M, Cutler D Grace M, Bordens R Cullen C, Harvey J Laughlin M, J Hepatol 2006 45 204 213 10.1016/j.jhep.2006.03.008 16780997
    • (2006) J Hepatol , vol.45 , pp. 204-213
    • Silva, M.1    Poo, J.2    Wagner, F.3    Jackson, M.4    Cutler, D.5    Grace, M.6    Bordens, R.7    Cullen, C.8    Harvey, J.9    Laughlin, M.10
  • 28
    • 13744258758 scopus 로고    scopus 로고
    • The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase
    • DOI 10.1128/JVI.79.3.1943-1947.2005
    • The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Leyssen P Balzarini J, De Clercq E Neyts J, J Virol 2005 79 1943 1947 10.1128/JVI.79.3.1943-1947.2005 15650220 (Pubitemid 40459141)
    • (2005) Journal of Virology , vol.79 , Issue.3 , pp. 1943-1947
    • Leyssen, P.1    Balzarini, J.2    De Clercq, E.3    Neyts, J.4
  • 32
    • 59149106172 scopus 로고    scopus 로고
    • What future for ribavirin?
    • 19207968
    • What future for ribavirin? Shiffman ML, Liver Int 2009 29 Suppl 1 68 73 19207968
    • (2009) Liver Int , vol.29 , Issue.SUPPL. 1 , pp. 68-73
    • Shiffman, M.L.1
  • 33
    • 30044432484 scopus 로고    scopus 로고
    • American gastroenterological association technical review on the management of hepatitis C
    • DOI 10.1053/j.gastro.2005.11.010, PII S0016508505022705
    • American Gastroenterological Association technical review on the management of hepatitis C. Dienstag JL McHutchison JG, Gastroenterology 2006 130 231 264 quiz 214-237 10.1053/j.gastro.2005.11.010 16401486 (Pubitemid 43049856)
    • (2006) Gastroenterology , vol.130 , Issue.1 , pp. 231-264
    • Dienstag, J.L.1    Mchutchison, J.G.2
  • 34
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • DOI 10.1016/S0140-6736(01)06102-5
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP McHutchison JG, Gordon SC Rustgi VK, Shiffman M Reindollar R, Goodman ZD Koury K, Ling M Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01) 06102-5 11583749 (Pubitemid 32913521)
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3    Rustgi, V.K.4    Shiffman, M.5    Reindollar, R.6    Goodman, Z.D.7    Koury, K.8    Ling, M.-H.9    Albrecht, J.K.10
  • 36
    • 77950624679 scopus 로고    scopus 로고
    • Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
    • 10.1002/hep.23489. 20162613
    • Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Petta S Camma C Scazzone C Tripodo C, Di Marco V Bono A, Cabibi D Licata G, Porcasi R Marchesini G, Craxi A,, Hepatology 2010 51 1158 1167 10.1002/hep.23489 20162613
    • (2010) Hepatology , vol.51 , pp. 1158-1167
    • Petta, S.1    Camma, C.2    Scazzone, C.3    Tripodo, C.4    Di Marco, V.5    Bono, A.6    Cabibi, D.7    Licata, G.8    Porcasi, R.9    Marchesini, G.10    Craxi, A.11
  • 40
    • 0036378296 scopus 로고    scopus 로고
    • Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C
    • 10.1046/j.1365-2893.2002.00376.x. 12225327
    • Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. Layden TJ Layden JE, Reddy KR Levy-Drummer RS, Poulakos J Neumann AU, J Viral Hepat 2002 9 334 339 10.1046/j.1365-2893.2002.00376.x 12225327
    • (2002) J Viral Hepat , vol.9 , pp. 334-339
    • Layden, T.J.1    Layden, J.E.2    Reddy, K.R.3    Levy-Drummer, R.S.4    Poulakos, J.5    Neumann, A.U.6
  • 41
    • 74049136040 scopus 로고    scopus 로고
    • Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
    • 10.1111/j.1365-2893.2009.01157.x. 19674282
    • Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. Rodriguez-Torres M Sulkowski MS Chung RT Hamzeh FM, Jensen DM,, J Viral Hepat 2010 17 139 147 10.1111/j.1365-2893.2009.01157.x 19674282
    • (2010) J Viral Hepat , vol.17 , pp. 139-147
    • Rodriguez-Torres, M.1    Sulkowski, M.S.2    Chung, R.T.3    Hamzeh, F.M.4    Jensen, D.M.5
  • 49
    • 59749090086 scopus 로고    scopus 로고
    • Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)
    • 10.1128/AAC.01081-08. 18936191
    • Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Flint M Mullen S Deatly AM Chen W, Miller LZ Ralston R, Broom C Emini EA, Howe AY,, Antimicrob Agents Chemother 2009 53 401 411 10.1128/AAC.01081-08 18936191
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 401-411
    • Flint, M.1    Mullen, S.2    Deatly, A.M.3    Chen, W.4    Miller, L.Z.5    Ralston, R.6    Broom, C.7    Emini, E.A.8    Howe, A.Y.9
  • 56
    • 23944482649 scopus 로고    scopus 로고
    • Challenges and successes in developing new therapies for hepatitis C
    • DOI 10.1038/nature04080
    • Challenges and successes in developing new therapies for hepatitis C. De Francesco R Migliaccio G, Nature 2005 436 953 960 10.1038/nature04080 16107835 (Pubitemid 41191671)
    • (2005) Nature , vol.436 , Issue.7053 , pp. 953-960
    • De Francesco, R.1    Migliaccio, G.2
  • 57
    • 14644389360 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin
    • DOI 10.1055/s-2005-864780
    • Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Brau N, Semin Liver Dis 2005 25 33 51 10.1055/s-2005-864780 15731996 (Pubitemid 40322349)
    • (2005) Seminars in Liver Disease , vol.25 , Issue.1 , pp. 33-51
    • Brau, N.1
  • 58
    • 79953870639 scopus 로고    scopus 로고
    • Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007
    • 10.1111/j.1365-2893.2010.01299.x. 20367803
    • Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Vellozzi C Buchacz K, Baker R Spradling PR, Richardson J Moorman A, Tedaldi E Durham M, Ward J Brooks JT, J Viral Hepat 2011 18 316 324 10.1111/j.1365-2893.2010.01299.x 20367803
    • (2011) J Viral Hepat , vol.18 , pp. 316-324
    • Vellozzi, C.1    Buchacz, K.2    Baker, R.3    Spradling, P.R.4    Richardson, J.5    Moorman, A.6    Tedaldi, E.7    Durham, M.8    Ward, J.9    Brooks, J.T.10
  • 60
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases
    • 10.1002/hep.24641. 21898493
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Ghany MG Nelson DR Strader DB Thomas DL, Seeff LB,, Hepatology 2011 54 1433 1444 10.1002/hep.24641 21898493
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 62
    • 0038352047 scopus 로고    scopus 로고
    • Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population
    • DOI 10.1001/jama.290.2.228
    • Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA Weinstein MC, Hammitt JK Goldie SJ, JAMA 2003 290 228 237 10.1001/jama.290.2.228 12851278 (Pubitemid 37430062)
    • (2003) Journal of the American Medical Association , vol.290 , Issue.2 , pp. 228-237
    • Salomon, J.A.1    Weinstein, M.C.2    Hammitt, J.K.3    Goldie, S.J.4
  • 63
    • 13644267743 scopus 로고    scopus 로고
    • Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security
    • Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Siebert U Sroczynski G, Int J Technol Assess Health Care 2005 21 55 65 15736515 (Pubitemid 40229369)
    • (2005) International Journal of Technology Assessment in Health Care , vol.21 , Issue.1 , pp. 55-65
    • Siebert, U.1    Sroczynski, G.2
  • 64
    • 33745696443 scopus 로고    scopus 로고
    • Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
    • 16194133
    • Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Malone DC Tran TT Poordad FF,, J Manag Care Pharm 2005 11 687 694 16194133
    • (2005) J Manag Care Pharm , vol.11 , pp. 687-694
    • Malone, D.C.1    Tran, T.T.2    Poordad, F.F.3
  • 65
    • 79952233518 scopus 로고    scopus 로고
    • Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States
    • 10.1002/hep.24131. 21319199
    • Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Stepanova M Kanwal F, El-Serag HB Younossi ZM, Hepatology 2011 53 737 745 10.1002/hep.24131 21319199
    • (2011) Hepatology , vol.53 , pp. 737-745
    • Stepanova, M.1    Kanwal, F.2    El-Serag, H.B.3    Younossi, Z.M.4
  • 66
    • 21244433445 scopus 로고    scopus 로고
    • Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase
    • DOI 10.1016/j.molcel.2005.05.014, PII S1097276505013201
    • Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Watashi K Ishii N Hijikata M Inoue D, Murata T Miyanari Y, Shimotohno K,, Mol Cell 2005 19 111 122 10.1016/j.molcel.2005.05.014 15989969 (Pubitemid 40884662)
    • (2005) Molecular Cell , vol.19 , Issue.1 , pp. 111-122
    • Watashi, K.1    Ishii, N.2    Hijikata, M.3    Inoue, D.4    Murata, T.5    Miyanari, Y.6    Shimotohno, K.7
  • 67
    • 62949181285 scopus 로고    scopus 로고
    • Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors
    • 10.1128/AAC.00939-08. 19104013
    • Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont L Kaptein S Paeshuyse J Vliegen I, Dumont JM Vuagniaux G, Neyts J,, Antimicrob Agents Chemother 2009 53 967 976 10.1128/AAC.00939-08 19104013
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 967-976
    • Coelmont, L.1    Kaptein, S.2    Paeshuyse, J.3    Vliegen, I.4    Dumont, J.M.5    Vuagniaux, G.6    Neyts, J.7
  • 71
    • 67651251216 scopus 로고    scopus 로고
    • Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides
    • 10.3748/wjg.15.1805. 19370775
    • Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. Keeffe EB Rossignol JF, World J Gastroenterol 2009 15 1805 1808 10.3748/wjg.15.1805 19370775
    • (2009) World J Gastroenterol , vol.15 , pp. 1805-1808
    • Keeffe, E.B.1    Rossignol, J.F.2
  • 72
    • 48449084880 scopus 로고    scopus 로고
    • Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
    • 10.1111/j.1365-2036.2008.03781.x. 18616643
    • Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Rossignol JF Kabil SM El-Gohary Y Elfert A, Keeffe EB,, Aliment Pharmacol Ther 2008 28 574 580 10.1111/j.1365-2036.2008.03781.x 18616643
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 574-580
    • Rossignol, J.F.1    Kabil, S.M.2    El-Gohary, Y.3    Elfert, A.4    Keeffe, E.B.5
  • 73
    • 37449014458 scopus 로고    scopus 로고
    • Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication
    • 10.1016/j.antiviral.2007.08.005. 17888524
    • Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Korba BE Montero AB Farrar K Gaye K, Mukerjee S Ayers MS, Rossignol JF,, Antiviral Res 2008 77 56 63 10.1016/j.antiviral.2007.08.005 17888524
    • (2008) Antiviral Res , vol.77 , pp. 56-63
    • Korba, B.E.1    Montero, A.B.2    Farrar, K.3    Gaye, K.4    Mukerjee, S.5    Ayers, M.S.6    Rossignol, J.F.7
  • 75
    • 2942643933 scopus 로고    scopus 로고
    • Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates
    • DOI 10.1128/JVI.78.13.6995-7003.2004
    • Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. Jeong SH Qiao M Nascimbeni M Hu Z, Rehermann B Murthy K, Liang TJ,, J Virol 2004 78 6995 7003 10.1128/JVI.78.13.6995-7003.2004 15194776 (Pubitemid 38781538)
    • (2004) Journal of Virology , vol.78 , Issue.13 , pp. 6995-7003
    • Jeong, S.-H.1    Qiao, M.2    Nascimbeni, M.3    Hu, Z.4    Rehermann, B.5    Murthy, K.6    Liang, T.J.7
  • 78
    • 30344446364 scopus 로고    scopus 로고
    • Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3
    • DOI 10.1099/vir.0.81423-0
    • Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. Yu H Huang H Xiang J Babiuk LA, van Drunen Littel-van den Hurk S,, J Gen Virol 2006 87 1 10 10.1099/vir.0.81423-0 16361412 (Pubitemid 43056938)
    • (2006) Journal of General Virology , vol.87 , Issue.1 , pp. 1-10
    • Yu, H.1    Huang, H.2    Xiang, J.3    Babiuk, L.A.4    Van Drunen Littel-Van Den Hurk, S.5
  • 79
    • 67650523019 scopus 로고    scopus 로고
    • Hepatitis C virus infection and immunomodulatory therapies
    • 10.1016/j.cld.2009.05.007. 19628156
    • Hepatitis C virus infection and immunomodulatory therapies. Forde KA Reddy KR, Clin Liver Dis 2009 13 391 401 10.1016/j.cld.2009.05.007 19628156
    • (2009) Clin Liver Dis , vol.13 , pp. 391-401
    • Forde, K.A.1    Reddy, K.R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.